永和智控(002795.SZ)：子公司擬1.082億元收購昆明醫科100%股權
格隆匯 9 月 25日丨永和智控(002795.SZ)公佈，公司全資子公司成都永和成醫療科技有限公司(“成都永和成”)擬以支付現金方式收購昆明醫科腫瘤醫院有限公司(“昆明醫科”)100%股權。此次交易完成後，昆明醫科成為成都永和成的全資子公司。
經昆明醫科股東會決定，同意龍巖市長峯網絡科技合夥企業(有限合夥)(“龍巖長峯”)、趙新、萬柳雯波、朱應紅、田雨坤、劉麗、唐勝民、劉先榮，將其所持昆明醫科100%股權轉讓給成都永和成。據此，經交易雙方協商，目標公司100%股權的交易對價為1.082億元。
昆明醫科腫瘤醫院位於昆明市滇池國家旅遊度假區滇池路。該物業建築面積約1.2萬平米，醫院擁有病牀100餘張，是一家集腫瘤篩查、腫瘤治療、腫瘤康復為一體的腫瘤專科醫院。
截至目前，醫院已取得《營業執照》、《醫療機構執業許可證》、《環評驗收批覆》、《消防驗收許可》、《大型設備配置許可證》、《放射診療許可》及社保定點醫院認證。
醫院設有腫瘤科、內科、醫學影像科：放射治療專業、醫學檢驗科、藥劑科等十多個科室。目前已配置了先進的大型診療設備，如頭部伽瑪刀、體部伽瑪刀、醫用直線加速器、體外高頻熱療機等，能夠全面開展核磁共振、CT、超聲等檢查以及全身各部位腫瘤的治療，滿足各類腫瘤患者的診療需求。
為拓展上市公司業務範圍，增強持續盈利能力和綜合實力，公司實施了向醫療健康產業的戰略轉型，此次收購的昆明醫科將作為公司醫療戰略拓展的重要補充。企業價值主要體現在核心競爭力上，醫院作為一個特殊的行業，核心競爭力是醫院在其長期的醫療實踐及經營活動中逐步積累的。昆明醫科目前尚未盈利，但從腫瘤精準放射治療的發展趨勢、地區醫療資源的整體需求、昆明醫科的精準服務定位以及已具備的人才和設備優勢等綜合考量，昆明醫科已具備一定的發展潛力和優勢。因此，公司經審慎決策，認為此次收購是公司長期戰略佈局的延續，有利於進一步完善公司在醫療行業的佈局，有利於公司可持續發展，符合公司整體的業務發展規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
